Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:

• Leerink Global Healthcare Conference
  Monday, March 9, 2026 – One-on-one meetings
  Wednesday, March 11, 2026 – Fireside chat at 9:20 a.m. ET

• Citizens Life Sciences Conference
  Tuesday, March 10, 2026 – One-on-one meetings
  Fireside chat at 2:15 p.m. ET

• Jefferies Biotech on the Beach Summit
  Wednesday, March 11, 2026 – One-on-one meetings only

• Barclays 28th Annual Global Healthcare Conference
  Thursday, March 12, 2026 – One-on-one meetings
  Fireside chat at 10:30 a.m. ET

Webcasts of the fireside chats at the Leerink, Citizens and Barclays conferences will be available via the Events section of the Altimmune website.

Registered investors may request meetings on the dates noted above via their sales contacts at the respective banks.

About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company’s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X

Investor Contact:
Lee Roth
Burns McClellan
[email protected]

Media Contact:
Real Chemistry
[email protected]

This press release was published by a CLEAR® Verified individual.

You May Also Be Interested In

• Gray Announces Pricing of $750 Million of 7.500% Senior Secured First Lien Notes due 2034
• Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
• KBRA Assigns Rating to Blue Owl Technology Finance Corp.'s $400 Million Senior Unsecured Notes due 2029